Bingyi Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bingyi Yang has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Xiaojun Chen
Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
6 shared publications - Jun Guan
Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
3 shared publications - Weiwei Shan
Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
3 shared publications - Hongwei Zhang
Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, Shanghai, China
2 shared publications - Liying Xie
Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
2 shared publications - Qiaoying Lv
Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
2 shared publications
Latest Publications
- 1 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (818) , eadp0064
Cholesterol desensitizes the response of endometrial cancer to progestin by attenuating progestin signaling
Progestin is the primary fertility-preserving treatment for patients with endometrial cancer (EC) and its precursor lesions, endometrial atypical hyperplasia (EAH); however, a subset of patients exhibits a poor response. In this study, through the analysis of serum lipid differences, we found that progestin-resistant patients with EC/EAH exhibited reduced serum apolipoprotein A-I concentrations and increased cholesterol accumulation in endometrial tissue. Mechanistically, molecular docking simulations and cellular models confirmed that cellular cholesterol interfered with progestin-driven signaling by competing with progestin for binding to progesterone receptor B (PRB), thereby impairing its phosphorylation, nuclear translocation, and downstream gene activation. Substitution of leucine 887 with alanine 887 in PRB disrupted cholesterol binding but preserved progestin responsiveness. Furthermore, cholesterol-lowering therapy with rosuvastatin calcium restored progestin sensitivity in animal models and in a single-arm, open-label phase 2 clinical trial. Our work shows that cholesterol accumulation contributes to progestin resistance and that combining progestin with statins may enhance therapeutic efficacy in EC.
- 1 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (818) , eadp0064
Cholesterol desensitizes the response of endometrial cancer to progestin by attenuating progestin signaling
Progestin is the primary fertility-preserving treatment for patients with endometrial cancer (EC) and its precursor lesions, endometrial atypical hyperplasia (EAH); however, a subset of patients exhibits a poor response. In this study, through the analysis of serum lipid differences, we found that progestin-resistant patients with EC/EAH exhibited reduced serum apolipoprotein A-I concentrations and increased cholesterol accumulation in endometrial tissue. Mechanistically, molecular docking simulations and cellular models confirmed that cellular cholesterol interfered with progestin-driven signaling by competing with progestin for binding to progesterone receptor B (PRB), thereby impairing its phosphorylation, nuclear translocation, and downstream gene activation. Substitution of leucine 887 with alanine 887 in PRB disrupted cholesterol binding but preserved progestin responsiveness. Furthermore, cholesterol-lowering therapy with rosuvastatin calcium restored progestin sensitivity in animal models and in a single-arm, open-label phase 2 clinical trial. Our work shows that cholesterol accumulation contributes to progestin resistance and that combining progestin with statins may enhance therapeutic efficacy in EC.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (6)
Pregnancy complications and outcomes in patients with early endometrial cancer or atypical hyperplasia after fertility-sparing treatment
Cheng Y, et al. J Gynecol Oncol. 2025 Apr;36:e111. https://doi.org/10.3802/jgo.2025.36.e111
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (6)
Open AccessPregnancy complications and outcomes in patients with early endometrial cancer or atypical hyperplasia after fertility-sparing treatment
Cheng Y, et al. J Gynecol Oncol. 2025 Apr;36:e111. https://doi.org/10.3802/jgo.2025.36.e111
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (1)
Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914)
Xu Z, et al. J Gynecol Oncol. 2022 Dec;34(1):e32. https://doi.org/10.3802/jgo.2023.34.e32
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (1)
Open AccessComparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914)
Xu Z, et al. J Gynecol Oncol. 2022 Dec;34(1):e32. https://doi.org/10.3802/jgo.2023.34.e32
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (4) , e57
Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
Zhou S, et al. J Gynecol Oncol. 2021 Apr;32(4):e57. https://doi.org/10.3802/jgo.2021.32.e57
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (4) , e57
Open AccessCharacteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
Zhou S, et al. J Gynecol Oncol. 2021 Apr;32(4):e57. https://doi.org/10.3802/jgo.2021.32.e57
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (2) , e39
Asian Society of Gynecologic Oncology International Workshop 2018
Kong TW, et al. J Gynecol Oncol. 2018 Aug;30:e39. https://doi.org/10.3802/jgo.2019.30.e39
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (2) , e39
Open AccessAsian Society of Gynecologic Oncology International Workshop 2018
Kong TW, et al. J Gynecol Oncol. 2018 Aug;30:e39. https://doi.org/10.3802/jgo.2019.30.e39
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (1) , e13
The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification
Guan J, et al. J Gynecol Oncol. 2018 Aug;30:e13. https://doi.org/10.3802/jgo.2019.30.e13
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (1) , e13
Open AccessThe prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification
Guan J, et al. J Gynecol Oncol. 2018 Aug;30:e13. https://doi.org/10.3802/jgo.2019.30.e13
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 29 (3) , e35
Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients
Yang B, et al. J Gynecol Oncol. 2017 Dec;29:e35. https://doi.org/10.3802/jgo.2018.29.e35
- 1 January 2018
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 29 (3) , e35
Open AccessInsulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients
Yang B, et al. J Gynecol Oncol. 2017 Dec;29:e35. https://doi.org/10.3802/jgo.2018.29.e35